盐酸氨溴索与异丙托溴铵雾化吸入治疗慢性阻塞性肺病患者临床观察

目的:探讨盐酸氨溴索与异丙托溴铵雾化吸入治疗对慢性阻塞性肺病患者的治疗效果。方法:将我院收治的86例COPD患者随机分为异丙托溴铵组和组合治疗组,异丙托溴铵组给予异丙托溴铵2ml+生理盐水3ml雾化吸入。组合治疗组除了常规治疗外加以盐酸氨溴索(沐舒坦)2ml+异丙托溴铵2ml+生理盐水1ml雾化吸入。测量治疗前、后FEV1、血氧饱和度、平均住院天数等指标。结果:异丙托溴铵组治疗前、后平均FEV1差值为(0.324±0.102)L,组合治疗组平均FEV1差值为(0.468±0.124)L,两组差异具有统计学意义(P<0.05)。异丙托溴铵组治疗的总有效率为81.4%,而组合治疗组的总有效率为88.4%,两组差异具有统计学意义(P<0.05)。组合治疗组治疗前、后血氧饱和度差值高于异丙托溴铵组(P<0.05)。结论:盐酸氨溴索和异丙托溴铵联合雾化吸入治疗COPD有助于患者症状好转,效果优于单一应用异丙托溴铵。

The Influence of Nebulizing Inhalation of Ambroxol Hydrochloride and Ipratropium Bromide in Treatment of Chronic Obstructive Pulmonary Disease

Objective:To study of the role of ambroxol hydrochloride and ipratropium bromide in treatment of chronic obstructive pulmonary disease(COPD).Methods:86 patients with COPD were randomly divided into two groups,ipratropium bromide group and combine group.Ipratropium bromide group were treated with nebulizing inhalation of ipratropium bromide,while combine group were treated with nebulizing inhalation of ambroxol hydrochloride and ipratropium bromide.Measuring oxyhemoglobin saturation、FEV1、mean hospitalization days of two groups.Results:FEV1 difference of ipratropium bromide group before or after therapy was(0.324±0.102)L,combine group was(0.468±0.124)L(P<0.05).Total efficiency of ipratropium bromide group was 81.4%,combine group was 88.4%(P<0.05).Conclusion:Combined use of ambroxol hydrochloride and ipratropium bromide has synergistic action for treatment of COPD.